Switch theme
Sign up to access all valuation multiples
Chengdu Kanghong Pharmaceutical Group Co Ltd is a pharmaceutical company. The company is engaged in the research and development, production, and sales of medicine, chemical medicine, and biological products.
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Kanghong Pharmaceutical has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Kanghong Pharmaceutical achieved revenue of $545M and an EBITDA of $191M.
Kanghong Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Kanghong Pharmaceutical valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $545M | n/a | XXX | XXX | XXX |
| Gross Profit | $448M | $413M | XXX | XXX | XXX |
| Gross Margin | 82% | NaN% | XXX | XXX | XXX |
| EBITDA | $191M | n/a | XXX | XXX | XXX |
| EBITDA Margin | 35% | NaN% | XXX | XXX | XXX |
| Net Profit | $58.0M | $124M | XXX | XXX | XXX |
| Net Margin | 11% | NaN% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Kanghong Pharmaceutical's stock price is CNY 28 (or $4).
Kanghong Pharmaceutical has current market cap of CNY 25.5B (or $3.5B), and EV of CNY 20.0B (or $2.7B).
See Kanghong Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.7B | $3.5B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Kanghong Pharmaceutical has market cap of $3.5B and EV of $2.7B.
Kanghong Pharmaceutical's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Kanghong Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Kanghong Pharmaceutical and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.7B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpKanghong Pharmaceutical's NTM/LTM revenue growth is n/a
Kanghong Pharmaceutical's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Kanghong Pharmaceutical's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Kanghong Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Kanghong Pharmaceutical and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 21% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 11% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 59% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kanghong Pharmaceutical acquired XXX companies to date.
Last acquisition by Kanghong Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . Kanghong Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Kanghong Pharmaceutical founded? | Kanghong Pharmaceutical was founded in 1996. |
| Where is Kanghong Pharmaceutical headquartered? | Kanghong Pharmaceutical is headquartered in China. |
| Is Kanghong Pharmaceutical publicy listed? | Yes, Kanghong Pharmaceutical is a public company listed on SHE. |
| What is the stock symbol of Kanghong Pharmaceutical? | Kanghong Pharmaceutical trades under 002773 ticker. |
| When did Kanghong Pharmaceutical go public? | Kanghong Pharmaceutical went public in 2015. |
| Who are competitors of Kanghong Pharmaceutical? | Similar companies to Kanghong Pharmaceutical include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Kanghong Pharmaceutical? | Kanghong Pharmaceutical's current market cap is $3.5B |
| Is Kanghong Pharmaceutical profitable? | Yes, Kanghong Pharmaceutical is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
